TheRealReal REAL 深 沪
等待开盘 01-23 09:30:00 美东时间
16.24
-0.340
-2.05%
华盛通- 最 高17.3922
- 今 开16.91
- 成交量 229.76万股
- 最 低 16.2014
- 昨 收 16.58
- 总市值 19.00亿
- 52周最高 17.3922
- 市盈率 静 --
- 换手率 1.96%
- 52周最低 4.61
- 委 比 -2.77%
- 总股本 1.17亿
- 历史最高 30.22
- 量 比 0.75
- 振 幅 7.18%
- 历史最低 1.00
- 每 手 1
- 风险率 3.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Keybanc Maintains Overweight on RealReal, Raises Price Target to $20
Keybanc analyst Ashley Owens maintains RealReal (NASDAQ:REAL) with a Overweight and raises the price target from $16 to $20.
01-22 20:39
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
UBS Maintains Neutral on RealReal, Raises Price Target to $16
UBS analyst Kunal Madhukar maintains RealReal (NASDAQ:REAL) with a Neutral and raises the price target from $14 to $16.
01-09 00:49
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
BTIG Maintains Buy on RealReal, Raises Price Target to $18
BTIG analyst Marvin Fong maintains RealReal (NASDAQ:REAL) with a Buy and raises the price target from $15 to $18.
2025-12-30 21:23
BTIG thinks RealReal's strong 2025 rally can extend into 2026
BTIG lifted its price target on The RealReal (REAL) to $18 on its view that the strong 2025 rally can extend into 2026. Analyst Marvin Fong said the firm continues to target a 4X EV/gross profit multi...
2025-12-30 19:47
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
William Blair Initiates Coverage On RealReal with Outperform Rating
William Blair analyst Dylan Carden initiates coverage on RealReal (NASDAQ:REAL) with a Outperform rating.
2025-12-15 23:47
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
B. Riley Securities Maintains Buy on RealReal, Raises Price Target to $17
B. Riley Securities analyst Anna Glaessgen maintains RealReal (NASDAQ:REAL) with a Buy and raises the price target from $14 to $17.
2025-12-12 22:58
